Voya Investment Management LLC increased its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 25.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,793 shares of the biopharmaceutical company’s stock after purchasing an additional 3,405 shares during the quarter. Voya Investment Management LLC’s holdings in Xencor were worth $355,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC boosted its holdings in Xencor by 77.7% during the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after purchasing an additional 2,924,510 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Xencor by 5.6% during the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after purchasing an additional 90,094 shares during the last quarter. State Street Corp boosted its holdings in Xencor by 17.5% during the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock worth $23,751,000 after purchasing an additional 148,136 shares during the last quarter. Northern Trust Corp boosted its holdings in Xencor by 6.6% during the second quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after purchasing an additional 30,715 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Xencor by 8.0% during the first quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock worth $8,783,000 after purchasing an additional 27,099 shares during the last quarter. Institutional investors and hedge funds own 76.81% of the company’s stock.

In related news, major shareholder John S. Stafford III acquired 13,700 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were bought at an average cost of $19.81 per share, with a total value of $271,397.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder John S. Stafford III acquired 79,035 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $20.47 per share, for a total transaction of $1,617,846.45. The disclosure for this purchase can be found here. Insiders bought 427,209 shares of company stock worth $8,537,686 over the last three months. Insiders own 4.03% of the company’s stock.

Xencor, Inc. (NASDAQ:XNCR) opened at $21.03 on Friday. Xencor, Inc. has a 1 year low of $18.55 and a 1 year high of $29.38.

Several brokerages recently commented on XNCR. Canaccord Genuity restated a “buy” rating and set a $36.00 target price on shares of Xencor in a report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.67.

TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/xencor-inc-xncr-shares-bought-by-voya-investment-management-llc/1697459.html.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.